The Ideal Platform for Building SARS-CoV-2 Vaccines
We believe our scalable vaccine technology has a critical role to play in the COVID-19 pandemic
A Unique Technology
Completely Natural
Hexamer vaccine scaffold is made of natural peptides, which can be quickly adjusted to target specific regions of a virus or variant mutation.
Stoichiometrically Controlled Reactions
Conjugation of antigens makes our technology unique because the reaction can be stoichiometrically controlled and used with a wide variety of different antigens to present both linear and conformational epitopes to the immune system.
Compatible With Wide Variety of Antigen
Attaching antigens using a conjugation approach is important because the scaffold is compatible with a wide variety of antigens including non-linear elements from an overall target (discontinuous, conformational), or regions from recently mutated variants, or large viral segments, or even small molecules. Therefore our technology has a wide variety of applications and a greater chance of presenting native epitopes.
Self-Assembling Scaffold
Hexamer's scaffold self-assembles into higher order structures in aqueous solution and is not immunogenic until antigenic targets are conjugated (linked) onto the structure.
Non-Immunogenic Scaffold
Regardless of the final structure, our scaffold remains non-immunogenic and focuses immune responses to the peptide antigen. This is important because our scaffold contains no immunodominant epitopes to mask immune responses against conjugated antigens.
Robust Immune Responses
When combined with a synergistic adjuvant, our vaccine technology has shown robust and durable immune responses, including a persistent depot effect predicting the potential for a single dose vaccine.
Specific Advantages of Hexamer Therapeutics Vaccine Platform
Fast
In about one week, vaccine developers can go from target sequence data to having candidate vaccines that are ready for testing.
Scalable
Highly scalable manufacturing because the scaffold carrier and antigenic tips are all made exclusively of natural peptides. A typical cGMP peptide manufacturer can make ~100 KG in ~6 months (~2 billion doses at 50µg each).
Optimal
Robust, durable immune responses that are balanced (Th1/Th2) when combined with appropriate adjuvant. We have strong evidence in preclinical trials for a persistent depot effect that could allow for a single dose vaccine.
Stable
The vaccine is stable at room temperature for distribution and storage. Suitable for stockpiling as a lyophilized powder for very long-term storage.
Powerful
Complete neutralization of live SARS-CoV2 virus; and preventing viral particles from entry into human cells in vitro.
Adaptable
Ideal for addressing mutant viral strains as a suite of variant-specific antigen targets can be mounted on the scaffold and then combined for a broad ranging and highly effective vaccine.
Versatile
The scaffold peptide can easily be modified to incorporate proprietary/patented human T-cell epitopes and hold a variety of antigenic targets.
Innovative
The technology is a self-assembling, natural, peptide scaffold platform that can be armed with a variety of different antigenic targets very quickly. We are building a portfolio of IP with PCT patents filed on the vaccine scaffold; loaded with a variety of peptides and small molecules for use in human and animal health.
Safe Components
Made entirely of natural peptides, there are no cells, no eggs, no killed virus, no large viral proteins and no biological recombinant elements are involved in the manufacturing process.
Hexamer’s Most Recent Vaccine Trials
Please contact Hexamer Therapeutics for an update on our SARS-CoV-2 vaccine trials, cGMP manufacturing progress and estimated FDA approval date. We will be accepting vaccine pre-orders when Phase 2/3 Human Clinical Trials begin.